Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of JNJ-54416076 Formulations
NCT02951845Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-54416076 (12 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration, Time to Reach Maximum Concentration and 3 more. Planned start Nov 2016; status: withdrawn.
02
Drugs
JNJ-54416076
Beyond the preview
Go deeper on NCT02951845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951845.